License Agreements (Details Textual) (USD $)	12 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Oct. 09, 2007
Rhode Island Hospital [Member]
Royalty Payment Commitment	5% until $550,000 has been paid, then 2% after that.
Amarin Neuroscience Limited [Member] | Milestones One [Member]
Future Royalties, Milestone Payments, Description	$500,000 upon first filing of a new drug application with Food and Drug Administration (FDA) or a reasonably similar filing with any regulatory authority for Active Agent Product.
Amarin Neuroscience Limited [Member] | Milestones Two [Member]
Future Royalties, Milestone Payments, Description	$1,000,000 upon first FDA approval for sale in the USA for Active Agent Product.
Amarin Neuroscience Limited [Member] | Milestones Three [Member]
Future Royalties, Milestone Payments, Description	$1,500,000 within twelve calendar months after the first sale in the USA for Active Agent Product.
Amarin Neuroscience Limited [Member] | Milestones Four [Member]
Future Royalties, Milestone Payments, Description	$1,000,000 within twelve calendar months after the first sale in the European Economic Area for Active Agent Product.
Corning Incorporated [Member]
Deferred Revenue, Revenue Recognized	$ 44,118	$ 44,118
Payments for Grant of License			375,000
Amortization Period for Deferred Revenue	17 years
Deferred Revenue	522,059	566,177
Pfizer Incorporated [Member]
Deferred Revenue, Revenue Recognized	5,200	5,200
Deferred Revenue	$ 26,000	$ 31,200